AbolerIS Pharma Raises €27.3M for Autoimmune Disease Drug Trial

AbolerIS Pharma Raises €27.3M for Autoimmune Disease Drug Trial

AbolerIS Pharma has secured €27.3 million in a Series A financing round, led by Caixa Capital Risc and co-led by Sound Bioventures and Newton Biocapital. The funding will support the development of the company's lead program, a monoclonal antibody targeting CD45RC, a novel molecular target for immune modulation in autoimmune diseases.

The funding round saw participation from SFPI-FPIM, WE, Sambrinvest, Investsud Tech, and Relyens Innovation Santé/Turenne Capital. Pablo Cironi, Director of Caixa Capital Risc, praised AbolerIS' innovative scientific approach, which aims to rebalance the immune system and prevent it from attacking the body's own cells, offering hope for long-lasting remission in autoimmune diseases.

AbolerIS' lead program targets CD45RC, a novel target for immune modulation discovered by co-founders Dr. Ignacio Anegon and Dr. Carole Guillonneau. The funding will accelerate the development of this program in clinical trials and explore its effectiveness in additional autoimmune diseases. Caroline Thielen, Investment Manager at WE Life Sciences, expressed support for AbolerIS' mission to bring new treatments to patients suffering from severe autoimmune disorders. Ann Meulemans, CEO of AbolerIS Pharma, committed to advancing these groundbreaking discoveries to the clinical stage as soon as possible.

AbolerIS Pharma has raised €27.3 million to advance its lead program targeting CD45RC in autoimmune diseases. The funding will support clinical trials and further exploration of the program's potential in additional autoimmune diseases. The company's innovative approach to immunotherapy offers hope for long-lasting remission in these conditions.

Read also:

• Inadequate supply of accessible housing overlooks London's disabled community
• Strange discovery in EU: Rabbits found with unusual appendages resembling tentacles on their heads
• Duration of a Travelling Blood Clot: Time Scale Explained
• Fainting versus Seizures: Overlaps, Distinctions, and Proper Responses